Many animal models of non-alcoholic steatohepatitis (NASH) have been developed which mirror various aspects of the disease and choosing the most appropriate is a key question faced by the pharmaceutical industry. The aim of this present study was to characterise RenaSci’s four dietary-induced NASH mouse models, specifically the methionine/choline deficient (MCD) diet mouse, choline deficient (CD) diet mouse, high-fat/fructose/cholesterol (H-FFC) diet mouse and the genetically-obese (ob/ob) H-FFC diet mouse. The efficacy of the clinically effective agents elafibranor and/or pioglitazone on histological end-points, plasma parameters and liver biochemistry were also assessed.
